The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl

被引:23
作者
Bryhn, M. [1 ]
Hansteen, H. [1 ]
Schanche, T. [1 ]
Aakre, S. E. [1 ]
机构
[1] Pronova Biocare, R&D, N-1327 Lysaker, Norway
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2006年 / 75卷 / 01期
关键词
D O I
10.1016/j.plefa.2006.04.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Omega-3 fatty acids have a long history of use as dietary supplements and more recently for therapeutic applications as prescription pharmaceuticals. Achieving a high concentration is critical for developing convenient, practical therapeutic formulations. The objective of the study was to explore the uptake and effects of different concentrations of omega-3 acid ethyl esters. Three different omega-3 concentrations were investigated in a clinical study with 101 subjects. All participants were dosed for 14 days with 5.1 g per day of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) ethyl esters provided in three concentrations: 62.5%, 80% and 85% of total fatty acids. Key endpoints of the study were serum phospholipids and standard fasting lipid panels at day 14. Although administered the same quantity of omega-3 fatty acids, the patients taking the more concentrated formulations had higher levels of EPA/DHA in serum phospholipids and greater reductions in serum triglyceride and VLDL cholesterol levels. Total and non-HDL cholesterol were significantly reduced from baseline with all three formulations. In conclusion the concentration of omega-3 fatty acids of the formulations studied had independent effects on the uptake and effect outcomes during short-term administration. Very high concentrations of omega-3 acid ethyl esters (>= 80%) appear to have higher uptake and are more potent for reducing triglycerides (TGs) and VLDL-cholesterol than formulation; with lower concentrations. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 21 条
[1]  
Balk E., 2004, AHRQ PUBL
[2]   The effect of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia [J].
Borthwick, L .
CLINICAL DRUG INVESTIGATION, 1998, 15 (05) :397-404
[3]  
Conquer JA, 1998, J LIPID RES, V39, P286
[4]   IMPROVEMENT OF SERUM-LIPIDS AND BLOOD-PRESSURE DURING INTERVENTION WITH N-3 FATTY-ACIDS WAS NOT ASSOCIATED WITH CHANGES IN INSULIN LEVELS IN SUBJECTS WITH COMBINED HYPERLIPIDEMIA [J].
GRUNDT, H ;
NILSEN, DWT ;
HETLAND, O ;
AARSLAND, T ;
BAKSAAS, I ;
GRANDE, T ;
WOIE, L .
JOURNAL OF INTERNAL MEDICINE, 1995, 237 (03) :249-259
[5]  
Harris W S, 1997, J Cardiovasc Risk, V4, P385, DOI 10.1097/00043798-199710000-00011
[6]   Are omega-3 fatty acids the most important nutritional modulators of coronary heart disease risk? [J].
Harris W.S. .
Current Atherosclerosis Reports, 2004, 6 (6) :447-452
[7]   n-3 Fatty acids and serum lipoproteins: Human studies [J].
Harris, WS .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1997, 65 (05) :1645-1654
[8]   Fatty acid regulation of gene transcription [J].
Jump, DB .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2004, 41 (01) :41-78
[9]   Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease [J].
Kris-Etherton, PM ;
Harris, WS ;
Appel, LJ .
CIRCULATION, 2002, 106 (21) :2747-2757
[10]   Requirement of PPARα in maintaining phospholipid and triacylglycerol homeostasis during energy deprivation [J].
Lee, SST ;
Chan, WY ;
Lo, CKC ;
Wan, DCC ;
Tsang, DSC ;
Cheung, WT .
JOURNAL OF LIPID RESEARCH, 2004, 45 (11) :2025-2037